Systemic treatment of hepatocellular carcinoma:Past,present and future
Systemic treatment of hepatocellular carcinoma: Past, present and future作者机构:Department of Medical OncologyRoyal Bournemouth HospitalBournemouth BH7 7DWUnited Kingdom
出 版 物:《World Journal of Hepatology》 (世界肝病学杂志(英文版)(电子版))
年 卷 期:2017年第9卷第18期
页 面:797-807页
学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题:Hepatocellular 癌 Alphafetoprotein Sorafenib Nivolumab MEK
摘 要:Hepatocellular carcinoma(HCC) is a common neoplasia which represents the second leading cause of cancer related death. Most cases occur in developing countries, but its incidence is rising in Western countries due to hepatitis C. Although hepatitis therapies have evolved and the HCC screening has increased in several areas, 40% present with advanced disease which is only amenable for palliative systemic treatment. HCC continues posing a challenge, in part due to the inherent chemoresistance of this neoplasia, the pharmacologic challenges due to an ill liver, difficulty in assessing radiological responses accurately, etc. Traditional chemotherapy have shown some responses without clear survival benefit, however, sorafenib demonstrated advantages in survival in advanced HCC when liver function is kept and recently immunotherapy seems to be a promising approach for some patients. This article will briefly expose the most relevant systemic treatment modalities to offer a general view from the past to the future.